| Methods |
2‐week placebo run‐in; inclusion criteria= sitting DBP 95‐115 mm Hg; 4‐week double‐blind treatment |
| Participants |
Imidapril 5 mg: n=33(21 males,12 females); mean age=53.2(12.1) years; baseline sitting DBP=102.3(5.7) mm Hg;
Imidapril 10 mg: n=31(18 males,13 females); mean age=52.3(11.7) years; baseline sitting DBP=100.8(4.5) mm Hg;
Imidapril 20 mg: n=31(16 males,15 females); mean age=52.5(10.0) years; baseline sitting DBP=101.0(5.6) mm Hg;
Imidapril 40 mg: n=32(21 males,11 females); mean age=49.8(13.6) years; baseline sitting DBP=102.2(5.1) mm Hg;
Placebo: n=35(20 males,15 females); mean age=51.9(11.8) years; baseline sitting DBP=101.3(5.3) mm Hg |
| Interventions |
Imidapril 5 mg once daily;
Imidapril 10 mg once daily;
Imidapril 20 mg once daily;
Imidapril 40 mg once daily;
Placebo |
| Outcomes |
Trough sitting SBP/DBP using mercury sphygmomanometer;
Trough standing SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SD of change reported; endpoint BP and SD reported; change in BP data from Table 4, p. 271; Jadad score=3; funding source= Tanabe Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
